FibroGen Inc (NASDAQ: FGEN) has seen a rise in its stock price by 4.46 in relation to its previous close of 1.12. However, the company has experienced a 18.87% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-04-29 that SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on Monday, May 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company’s corporate and financial performance.
Is It Worth Investing in FibroGen Inc (NASDAQ: FGEN) Right Now?
FGEN has 36-month beta value of 0.88. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 5 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for FGEN is 92.43M, and currently, short sellers hold a 5.87% ratio of that float. The average trading volume of FGEN on May 02, 2024 was 2.27M shares.
FGEN’s Market Performance
FGEN stock saw a decrease of 18.87% in the past week, with a monthly decline of -45.83% and a quarterly a decrease of -39.06%. The volatility ratio for the week is 12.28%, and the volatility levels for the last 30 days are 15.79% for FibroGen Inc (FGEN). The simple moving average for the past 20 days is -8.47% for FGEN’s stock, with a -5.48% simple moving average for the past 200 days.
Analysts’ Opinion of FGEN
Many brokerage firms have already submitted their reports for FGEN stocks, with BofA Securities repeating the rating for FGEN by listing it as a “Underperform.” The predicted price for FGEN in the upcoming period, according to BofA Securities is $2 based on the research report published on August 08, 2023 of the previous year 2023.
FGEN Trading at -33.41% from the 50-Day Moving Average
After a stumble in the market that brought FGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.99% of loss for the given period.
Volatility was left at 15.79%, however, over the last 30 days, the volatility rate increased by 12.28%, as shares sank -20.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.00% lower at present.
During the last 5 trading sessions, FGEN rose by +18.87%, which changed the moving average for the period of 200-days by -55.68% in comparison to the 20-day moving average, which settled at $1.2632. In addition, FibroGen Inc saw 32.01% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FGEN starting from Wettig Thane, who purchase 50,000 shares at the price of $1.91 back on Mar 07 ’24. After this action, Wettig Thane now owns 470,178 shares of FibroGen Inc, valued at $95,470 using the latest closing price.
Henderson Jeffrey William, the Director of FibroGen Inc, sale 2,000 shares at $1.03 during a trade that took place back on Sep 01 ’23, which means that Henderson Jeffrey William is holding 28,866 shares at $2,060 based on the most recent closing price.
Stock Fundamentals for FGEN
Current profitability levels for the company are sitting at:
- -1.91 for the present operating margin
- 0.87 for the gross margin
The net margin for FibroGen Inc stands at -1.93. The total capital return value is set at -1.37. Equity return is now at value -42790.17, with -55.00 for asset returns.
Based on FibroGen Inc (FGEN), the company’s capital structure generated -1.03 points at debt to capital in total, while cash flow to debt ratio is standing at -3.03. The debt to equity ratio resting at -0.51. The interest coverage ratio of the stock is -18.15.
Currently, EBITDA for the company is -259.28 million with net debt to EBITDA at -0.22. When we switch over and look at the enterprise to sales, we see a ratio of 1.17. The receivables turnover for the company is 3.6for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.52.
Conclusion
To put it simply, FibroGen Inc (FGEN) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
